Купить (150 RUB)
|сгенерировать QR код
Открытый доступ
Доступ платный или только для Подписчиков
Перспективы бариатрической хирургии в ведении пациентов с неалкогольной жировой болезнью печени
https://doi.org/10.33667/2078-5631-2023-28-29-32
Аннотация
Эпидемия ожирения в мире сопровождается значительным увеличением числа случаев неалкогольной жировой болезни печени (НАЖБП). Одним из направлений является бариатрическая хирургия. В представленной обзорной статье приводится анализ краткосрочной и долгосрочной эффективности применения методов бариатрической хирургии у пациентов с НАЖБП. Отмечены аспекты влияния бариатрической хирургии на биохимические и гистологические показатели фиброза печени, изменения инсулинорезистентности и липидного профиля, кишечный микробиом, участвующий в гомеостазе оси «кишечник – печень». Представлена роль полиморфизмов генов в прогрессировании НАЖБП, а также защите от фиброзных изменений у пациентов в послеоперационном периоде.
Ключевые слова
Об авторе
В. А. Ахмедов
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России
Россия
Россия
Ахмедов Вадим Адильевич, д. м. н., проф., зав. кафедрой медицинской реабилитации дополнительного профессионального образования
Scopus: 6603891660; Web of Science: AAU-3847–2020
г. Омск
Список литературы
1. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M. et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019; 7: 231–240. DOI: 10.1016/S2213–8587(19)30026–9.
2. Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021; 75: 284–291. DOI: 10.1016/j.jhep.2021.02.034.
3. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014; 59: 2188–2195. DOI: 10.1002/hep.26986.
4. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367–378. DOI: 10.1053/j.gastro.2015.04.005.
5. Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS One 2014; 9: e111808. DOI: 10.1371/journal.pone.0111808.
6. Lønsmann I, Steen Pedersen J, Krag A, Hansen T, Karsdal M, Julie Leeming D, Juul Nielsen M, Bendtsen F. Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease. Clin Biochem. 2023; 113: 29–35. DOI: 10.1016/j.clinbiochem.2022.12.012.
7. Jaroenlapnopparat A, Thompson CC, Jirapinyo P. Effect of Transoral Outlet Reduction on Hepatic Fibrosis in Roux-en-Y Gastric Bypass Patients with Weight Regain and Non-alcoholic Fatty Liver Disease. Obes Surg. 2023; 33(8): 2303–2310. DOI: 10.1007/s11695–023–06668–2.
8. Schwenger KJP, Ghorbani Y, Rezaei K, Fischer SE, Jackson TD, Okrainec A, Allard JP. Relationship between dietary intake components and hepatic fibrosis in those with obesity before and 1 year after bariatric surgery. Nutrition. 2023; 114: 112095. DOI: 10.1016/j.nut.2023.112095.
9. Poljo A, Kopf S, Sulaj A, Roessler S, Albrecht T, Goeppert B, Bojko S, Müller-Stich BP, Billeter AT. The role of bariatric surgery on beta-cell function and insulin resistance in patients with nonalcoholic fatty liver disease and steatohepatitis. Surg Obes Relat Dis. 2023: S1550–7289(23)00600–7. DOI: 10.1016/j.soard.2023.07.005.
10. Wang G, Huang Y, Yang H, Lin H, Zhou S, Qian J. Impacts of bariatric surgery on adverse liver outcomes: A systematic review and meta-analysis. Surg Obes Relat Dis. 2023; 19 (7): 717–726. DOI: 10.1016/j.soard.2022.12.025.
11. Sabench F, Bertran L, Vives M, París M, Aguilar C, Martínez S, Binetti J, Real M, Alibalic A, Richart C, Del Castillo D, Auguet T. NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity. Obes Surg. 2022; 32 (10): 3313–3323. DOI: 10.1007/s11695–022–06175-w.
12. Lalloyer F, Mogilenko DA, Verrijken A, Haas JT, Lamazière A, Kouach M, Descat A, Caron S, Vallez E, Derudas B, Gheeraert C, Baugé E, Despres G, Dirinck E, Tailleux A, Dombrowicz D, Van Gaal L, Eeckhoute J, Lefebvre P, Goossens JF, Francque S, Staels Roux-en-Y. Gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis. B.J Hepatol. 2023: S0168–8278(23)00341–0. DOI: 10.1016/j.jhep.2023.05.012.
13. Wang G, Wang Y, Bai J, Li G, Liu Y, Deng S, Zhou R, Tao K, Xia Z. Increased plasma genistein after bariatric surgery could promote remission of NAFLD in patients with obesity. Front Endocrinol (Lausanne). 2023; 13: 1024769. DOI: 10.3389/fendo.2022.1024769.
14. Cheng X, Fu Z, Xie W, Zhu L, Meng J. Preoperative circulating peroxiredoxin 1 levels as a predictor of non-alcoholic fatty liver disease remission after laparoscopic bariatric surgery. Front Endocrinol (Lausanne). 2022; 13: 1072513. DOI: 10.3389/fendo.2022.1072513.
15. Huang Y, Dong S, Wang C, Dong Z, Chen W. Significant fibrosis assessed by liver biopsy among Chinese bariatric surgery patients: A prospective cross-sectional study. Front Endocrinol (Lausanne). 2023; 14: 1090598. DOI: 10.3389/fendo.2023.1090598.
16. Xia Y, Ren M, Yang J, Cai C, Cheng W, Zhou X, Lu D, Ji F. Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. Front Micro-biol. 2022; 13: 1003755. DOI: 10.3389/fmicb.2022.1003755. eCollection 2022.
17. Maestri M, Santopaolo F, Pompili M, Gasbarrini A and Ponziani FR. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Front. Nutr. 2023; 10:1110536. DOI: 10.3389/fnut.2023.1110536.
18. Kalinowski P, Smyk W, Nowosad M, Paluszkiewicz R, Michałowski Ł, Ziarkiewicz-Wróblewska B, Weber SN, Milkiewicz P, Lammert F, Zieniewicz K, Krawczyk M. MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. Int J Mol Sci. 2022; 23 (24): 15825. DOI: 10.3390/ijms232415825.
19. Pedersen JS, Rygg MO, Serizawa RR, Kristiansen VB, Albrechtsen NJW, Gluud LL, Madsbad S, Bendtsen F. Effects of Roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: A 12-month follow-up study with paired liver biopsies. J Clin Med 2021; 10: 3783. DOI: 10.3390/jcm10173783.
20. Jirapinyo P, McCarty TR, Dolan RD, Shah R, Thompson CC. Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 511–524. e1. DOI: 10.1016/j.cgh.2021.03.017.
21. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388–1402. DOI: 10.1016/j.jhep.2015.11.004.
22. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328–357. DOI: 10.1002/hep.29367.
Рецензия
Для цитирования:
Ахмедов В.А. Перспективы бариатрической хирургии в ведении пациентов с неалкогольной жировой болезнью печени. Медицинский алфавит. 2023;(28):29-32. https://doi.org/10.33667/2078-5631-2023-28-29-32
For citation:
Akhmedov V.A. Prospects of bariatric surgery in management of patients with non-alcoholic fatty liver disease. Medical alphabet. 2023;(28):29-32. (In Russ.) https://doi.org/10.33667/2078-5631-2023-28-29-32
Просмотров:
214
Послать статью по эл. почте 